In addition, CD86, an activation receptor found on several immune cell types, including B cells, NK cells, and monocytes/macrophages38,39, was also more highly expressed by tumor-infiltrating cells in PRL3-zumab-treated tumor sections (Supplementary Fig. 7e, f). This evidence concerns the gene PTP4A3 and neoplasm.